Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

Pfizer88 enrolled

Overview

Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Alcoholism

Interventions

CP-866,087DRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject meets the DSM-IV criterion for current alcohol dependence. * Subject is currently not engaged in, and does not want, treatment for alcohol related problems. Exclusion Criteria: * Subject meets criteria for current DSM-IV diagnosis for any other psychoactive substance abuse or dependence disorder, excluding nicotine and caffeine. * Specialized inpatient or outpatient alcoholism or other addiction treatment (except nicotine) within the past 12 months.

Locations (11)

Pfizer Investigational Site

Cerritos, California, United States

Pfizer Investigational Site

New Haven, Connecticut, United States

Pfizer Investigational Site

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

The amount of alcohol consumed will be based on the total number of standardized drinks consumed during a two-hour laboratory-based self-administration procedure following 7 days of treatment with study medication.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.